NanoViricides begins Phase II trial of NV-387 oral gummies for Bundibugyo Ebola in DRC

• NanoViricides outlined progress in its Phase II trial of NV-387 oral gummies for Bundibugyo Ebola in the Democratic Republic of Congo.
• No clinical results were presented; Phase IIA enrollment began around Sept. 23, 2026, with efficacy readouts expected in a later randomized Phase IIB.
• Phase IIA aims to identify a tolerable dosing regimen in Ebola patients to support a go/no-go decision for Phase IIB.
• The company expects an optimal regimen to show signs of viral-load reduction and potential recovery, without claiming statistically proven benefit at this stage.
• The update framed an oral therapy as easier to deploy than infusion-based approaches as the outbreak expands, with 4,018 deaths reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610050845ACCESSWRNAPR_____1232663) on October 05, 2026, and is solely responsible for the information contained therein.